A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge

The development of tuberculosis (TB) vaccines has been hindered by the complex nature of Mycobacterium tuberculosis (M.tb) and the absence of clearly defined immune markers of protection. While Bacillus Calmette-Guerin (BCG) is currently the only licensed TB vaccine, its effectiveness diminishes in...

Descripción completa

Detalles Bibliográficos
Autores principales: Stylianou, Elena, Pinpathomrat, Nawamin, Sampson, Oliver, Richard, Alexandre, Korompis, Marcellus, McShane, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585038/
https://www.ncbi.nlm.nih.gov/pubmed/37869008
http://dx.doi.org/10.3389/fimmu.2023.1263457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585038/
https://www.ncbi.nlm.nih.gov/pubmed/37869008
http://dx.doi.org/10.3389/fimmu.2023.1263457

Ejemplares similares